Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day

R(+) pramipexole dihydrochloride monohydrate [R(+)PPX], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.

Inclusion Criteria:

• Definite diagnosis of ALS

Exclusion Criteria:

• No prior participation in R(+)PPX clinical studies